Novel tumor suppressor candidates on chromosome 3 revealed by NotI-microarrays in cervical cancer

Epigenetics

Volumn 8, Issue 4, 2013, Pages 409-420

  Senchenko, Vera N ^a   Kisseljova, Natalia P ^b   Ivanova, Tatyana A ^b,c,h   Dmitriev, Alexey A ^a   Krasnov, George S ^a,d   Kudryavtseva, Anna V ^a   Panasenko, Grigory V ^e   Tsitrin, Evgeny B ^f   Lerman, Michael I ^g   Kisseljov, Fyodor L ^b   Kashuba, Vladimir I ^e   Zabarovsky, Eugene R ^c  

^a ENGELHARDT INSTITUTE OF MOLECULAR BIOLOGY   (Russian Federation)

^b INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

^c KAROLINSKA INSTITUTE   (Sweden)

^d MECHNIKOV RESEARCH INSTITUTE FOR VACCINES AND SERA   (Russian Federation)

^e INSTITUTE OF MOLECULAR BIOLOGY AND GENETICS   (Ukraine)

^f KOL TSOV INSTITUTE OF DEVELOPMENTAL BIOLOGY   (Russian Federation)

^g Affina Biotechnologies   (United States)

^h Vela Research   (Singapore)

Author keywords

Cervical cancer; Chromosome 3; Deletions; DNA methylation; Expression; NotI microarrays; Tumor suppressors genes

Indexed keywords

BISULFITE; EPHRIN RECEPTOR B1; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; VON HIPPEL LINDAU PROTEIN; GCGGCCGC-SPECIFIC TYPE II DEOXYRIBONUCLEASES; RASSF1 PROTEIN, HUMAN; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN; TYPE II SITE SPECIFIC DEOXYRIBONUCLEASE;

ADENOCARCINOMA; ARTICLE; CANCER CELL CULTURE; CHROMOSOME 3; CLINICAL ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DNA METHYLATION; DNA MICROARRAY; DOWN REGULATION; EPIGENETICS; GENE DELETION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CANCER; CHEMISTRY; FEMALE; GENE EXPRESSION PROFILING; GENETIC EPIGENESIS; GENETICS; METABOLISM; MUTATION RATE; NUCLEOTIDE SEQUENCE; UTERINE CERVIX TUMOR;

ADENOCARCINOMA; BASE SEQUENCE; CARCINOMA, SQUAMOUS CELL; CHROMOSOMES, HUMAN, PAIR 3; DEOXYRIBONUCLEASES, TYPE II SITE-SPECIFIC; DNA METHYLATION; DOWN-REGULATION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION PROFILING; GENES, TUMOR SUPPRESSOR; HUMANS; MUTATION RATE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; SEQUENCE DELETION; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS; UTERINE CERVICAL NEOPLASMS;

EID: 84875824267     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/epi.24233     Document Type: Article

References (41)

1. zur Hausen H. Papillomaviruses--to vaccination and beyond. Biochemistry (Mosc) 2008; 73:498-503; PMID:18605974; http://dx.doi.org/10.1134/ S0006297908050027.
2. Hesson LB, Cooper WN, Latif F. Evaluation of the 3p21.3 tumour-suppressor gene cluster. Oncogene 2007; 26:7283-301; PMID:17533367; http://dx.doi. org/10.1038/sj.onc.1210547.
3. Ji L, Minna JD, Roth JA. 3p21.3 tumor suppressor cluster: prospects for translational applications. Future Oncol 2005; 1:79-92; PMID:16555978; http://dx.doi. org/10.1517/14796694.1.1.79.
4. Senchenko V, Liu J, Braga E, Mazurenko N, Loginov W, Seryogin Y, et al. Deletion mapping using quantitative real-time PCR identifies two distinct 3p21.3 regions affected in most cervical carcinomas. Oncogene 2003; 22:2984-92; PMID:12771950; http://dx.doi. org/10.1038/sj.onc.1206429.
5. Senchenko VN, Liu J, Loginov W, Bazov I, Angeloni D, Seryogin Y, et al. Discovery of frequent homozygous deletions in chromosome 3p21.3 LUCA and AP20 regions in renal, lung and breast carcinomas. Oncogene 2004; 23:5719-28; PMID:15208675; http://dx.doi. org/10.1038/sj.onc.1207760.
6. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis 2010; 31:27-36; PMID:19752007; http://dx.doi.org/10.1093/carcin/bgp220.
7. Dmitriev AA, Kashuba VI, Haraldson K, Senchenko VN, Pavlova TV, Kudryavtseva AV, et al. Genetic and epigenetic analysis of non-small cell lung cancer with NotI-microarrays. Epigenetics 2012; 7:502-13; PMID:22491060; http://dx.doi.org/10.4161/ epi.19801.
8. Kashuba V, Dmitriev AA, Krasnov GS, Pavlova T, Ignatjev I, Gordiyuk VV, et al. NotI Microarrays: Novel Epigenetic Markers for Early Detection and Prognosis of High Grade Serous Ovarian Cancer. Int J Mol Sci 2012; 13:13352-77; PMID:23202957; http://dx.doi. org/10.3390/ijms131013352.
9. Gerashchenko GV, Gordiyuk VV, Skrypkina IY, Kvasha SM, Kolesnik OO, Ugryn DD, et al. Screening of epigenetic and genetic disturbances of human chromosome 3 genes in colorectal cancer. Ukr Biokhim Zh 2009; 81:81-7; PMID:20387637.
10. Li J, Protopopov A, Wang F, Senchenko V, Petushkov V, Vorontsova O, et al. NotI subtraction and NotIspecific microarrays to detect copy number and methylation changes in whole genomes. Proc Natl Acad Sci U S A 2002; 99:10724-9; PMID:12149436; http:// dx.doi.org/10.1073/pnas.132271699.
11. Zabarovsky ER, Boldog F, Thompson T, Scanlon D, Winberg G, Marcsek Z, et al. Construction of a human chromosome 3 specific NotI linking library using a novel cloning procedure. Nucleic Acids Res 1990; 18:6319-24; PMID:2243778; http://dx.doi. org/10.1093/nar/18.21.6319.
12. Kashuba VI, Gizatullin RZ, Protopopov AI, Li J, Vorobieva NV, Fedorova L, et al. Analysis of NotI linking clones isolated from human chromosome 3 specific libraries. Gene 1999; 239:259-71; PMID:10548727; http://dx.doi.org/10.1016/S0378-1119(99)00411-4.
13. Gerashchenko GV, Bogatyrova OO, Rudenko EE, Kondratov AG, Gordiyuk VV, Zgonnyk YM, et al. Genetic and epigenetic changes of NKIRAS1 gene in human renal cell carcinomas. Exp Oncol 2010; 32:71-5; PMID:20693965.
14. Senchenko VN, Anedchenko EA, Kondratieva TT, Krasnov GS, Dmitriev AA, Zabarovska VI, et al. Simultaneous down-regulation of tumor suppressor genes RBSP3/CTDSPL, NPRL2/G21 and RASSF1A in primary non-small cell lung cancer. BMC Cancer 2010; 10:75; PMID:20193080; http://dx.doi. org/10.1186/1471-2407-10-75.
15. Dammann R, Schagdarsurengin U, Seidel C, Strunnikova M, Rastetter M, Baier K, et al. The tumor suppressor RASSF1A in human carcinogenesis: an update. Histol Histopathol 2005; 20:645-63; PMID:15736067.
16. Kuzmin I, Liu L, Dammann R, Geil L, Stanbridge EJ, Wilczynski SP, et al. Inactivation of RAS association domain family 1A gene in cervical carcinomas and the role of human papillomavirus infection. Cancer Res 2003; 63:1888-93; PMID:12702579.
17. Seoud M, Tjalma WA, Ronsse V. Cervical adenocarcinoma: moving towards better prevention. Vaccine 2011; 29:9148-58; PMID:21983356; http://dx.doi. org/10.1016/j.vaccine.2011.09.115.
18. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A 1999; 96:8681-6; PMID:10411935; http://dx.doi. org/10.1073/pnas.96.15.8681.
19. Lendvai A, Johannes F, Grimm C, Eijsink JJ, Wardenaar R, Volders HH, et al. Genome-wide methylation profiling identifies hypermethylated biomarkers in highgrade cervical intraepithelial neoplasia. Epigenetics 2012; 7:1268-78; PMID:23018867; http://dx.doi. org/10.4161/epi.22301.
20. Overmeer RM, Louwers JA, Meijer CJ, van Kemenade FJ, Hesselink AT, Daalmeijer NF, et al. Combined CADM1 and MAL promoter methylation analysis to detect (pre-)malignant cervical lesions in high-risk HPV-positive women. Int J Cancer 2011; 129:2218-25; PMID:21190187; http://dx.doi.org/10.1002/ ijc.25890.
21. Reesink-Peters N, Wisman GB, Jeronimo C, Tokumaru CY, Cohen Y, Dong SM, et al. Detecting cervical cancer by quantitative promoter hypermethylation assay on cervical scrapings: a feasibility study. Mol Cancer Res 2004; 2:289-95; PMID:15192122.
22. Widschwendter A, Gattringer C, Ivarsson L, Fiegl H, Schneitter A, Ramoni A, et al. Analysis of aberrant DNA methylation and human papillomavirus DNA in cervicovaginal specimens to detect invasive cervical cancer and its precursors. Clin Cancer Res 2004; 10:3396-400; PMID:15161694; http://dx.doi. org/10.1158/1078-0432.CCR-03-0143.
23. Anedchenko EA, Kiseleva NP, Dmitriev AA, Kiselev FL, Zabarovskiǐ ER, Senchenko VN. Tumor suppressor gene RBSP3 in cervical carcinoma: copy number and transcriptional level. Mol Biol (Mosk) 2007; 41:86-95; PMID:17380895; http://dx.doi.org/10.1134/ S0026893307010116.
24. Mitra S, Mazumder Indra D, Bhattacharya N, Singh RK, Basu PS, Mondal RK, et al. RBSP3 is frequently altered in premalignant cervical lesions: clinical and prognostic significance. Genes Chromosomes Cancer 2010; 49:155-70; PMID:19885927.
25. Protopopov A, Kashuba V, Zabarovska VI, Muravenko OV, Lerman MI, Klein G, et al. An integrated physical and gene map of the 3.5-Mb chromosome 3p21.3 (AP20) region implicated in major human epithelial malignancies. Cancer Res 2003; 63:404-12; PMID:12543795.
26. Leris AC, Roberts TR, Jiang WG, Newbold RF, Mokbel K. Evidence for a tumour suppressive function of APRG1 in breast cancer. Breast Cancer Res Treat 2005; 93:97-100; PMID:16187228; http://dx.doi. org/10.1007/s10549-005-4169-z.
27. Mahajan-Miklos S, Cooley L. The villin-like protein encoded by the Drosophila quail gene is required for actin bundle assembly during oogenesis. Cell 1994; 78:291-301; PMID:8044841; http://dx.doi. org/10.1016/0092-8674(94)90298-4.
28. Zhang MQ, Lin F, Hui P, Chen ZM, Ritter JH, Wang HL. Expression of mucins, SIMA, villin, and CDX2 in small-intestinal adenocarcinoma. Am J Clin Pathol 2007; 128:808-16; PMID:17951204; http://dx.doi. org/10.1309/JAF3KVGJHQCJ1QF9.
29. Kennedy MT, Jordan RC, Berean KW, Perez-Ordonez B. Expression pattern of CK7, CK20, CDX-2, and villin in intestinal-type sinonasal adenocarcinoma. J Clin Pathol 2004; 57:932-7; PMID:15333652; http:// dx.doi.org/10.1136/jcp.2004.016964.
30. Anedchenko EA, Dmitriev AA, Krasnov GS, Kondrat'eva TT, Kopantsev EP, Vinogradova TV, et al. Down-regulation of RBSP3/CTDSPL, NPRL2/G21, RASSF1A, ITGA9, HYAL1 and HYAL2 genes in nonsmall cell lung cancer. Mol Biol (Mosk) 2008; 42:965-76; PMID:19140316; http://dx.doi.org/10.1134/ S0026893308060058.
31. Tsang JS, Ebert MS, van Oudenaarden A. Genomewide dissection of microRNA functions and cotargeting networks using gene set signatures. Mol Cell 2010; 38:140-53; PMID:20385095; http://dx.doi. org/10.1016/j.molcel.2010.03.007.
32. Weber F, Teresi RE, Broelsch CE, Frilling A, Eng C. A limited set of human MicroRNA is deregulated in follicular thyroid carcinoma. J Clin Endocrinol Metab 2006; 91:3584-91; PMID:16822819; http://dx.doi. org/10.1210/jc.2006-0693.
33. Selth LA, Townley S, Gillis JL, Ochnik AM, Murti K, Macfarlane RJ, et al. Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease. Int J Cancer 2012; 131:652-61; PMID:22052531; http://dx.doi.org/10.1002/ ijc.26405.
34. Scapoli L, Palmieri A, Lo Muzio L, Pezzetti F, Rubini C, Girardi A, et al. MicroRNA expression profiling of oral carcinoma identifies new markers of tumor progression. Int J Immunopathol Pharmacol 2010; 23:1229-34; PMID:21244772.
35. Frigola J, Song J, Stirzaker C, Hinshelwood RA, Peinado MA, Clark SJ. Epigenetic remodeling in colorectal cancer results in coordinate gene suppression across an entire chromosome band. Nat Genet 2006; 38:540-9; PMID:16642018; http://dx.doi. org/10.1038/ng1781.
36. Coolen MW, Stirzaker C, Song JZ, Statham AL, Kassir Z, Moreno CS, et al. Consolidation of the cancer genome into domains of repressive chromatin by long-range epigenetic silencing (LRES) reduces transcriptional plasticity. Nat Cell Biol 2010; 12:235-46; PMID:20173741.
37. Dunwell TL, Hesson LB, Pavlova T, Zabarovska V, Kashuba V, Catchpoole D, et al. Epigenetic analysis of childhood acute lymphoblastic leukemia. Epigenetics 2009; 4:185-93; PMID:19430199; http://dx.doi. org/10.4161/epi.4.3.8752.
38. Krasnov GS, Oparina NIu, Dmitriev AA, Kudriavtsev AV, Anedchenko EA, Kondrat'eva TT, et al. Novel reference gene RPN1 for normalization of quantitative data in lung and kidney cancer. Mol Biol (Mosk) 2011; 45:238-48; PMID:21634111; http://dx.doi. org/10.1134/S0026893311020129.
39. Senchenko VN, Krasnov GS, Dmitriev AA, Kudryavtseva AV, Anedchenko EA, Braga EA, et al. Differential expression of CHL1 gene during development of major human cancers. PLoS One 2011; 6:e15612; PMID:21408220; http://dx.doi. org/10.1371/journal.pone.0015612.
40. Glantz SA. Primer of biostatistics. New York, USA: McGRAW-HILL, 2005.
41. Altman DG, Bland JM. Diagnostic tests. 1: Sensitivity and specificity. BMJ 1994; 308:1552; PMID:8019315; http://dx.doi.org/10.1136/bmj.308.6943.1552.